HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral

Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

NEUP

0.00

HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ: NEUP) from Buy to Neutral.